Lexaria Intends to Complete a $900,000 Financing

(the “Company” or “Lexaria”) reports its intention to complete a non-brokered private placement financing, consisting of 6,000,000 Equity Units at US $0.15 per unit, to raise gross proceeds of up to US $900,000 (the “Private Placement”).

Each equity unit will consist of one common share of the Company and one non-transferable share purchase warrant, each warrant entitling the holder to purchase one additional common share of the Company for a period of eighteen months from the date of issuance, at a purchase price of US$0.25. The Company may accelerate the expiry date of the warrants if the stock price trades above CAD$0.60 for 20 consecutive days at any time after 6 months and one day has elapsed.

Lexaria may pay broker commissions of up to 6.0% in cash and 6% in broker warrants in connection with the Private Placement. Each broker’s warrant will be exercisable into one single common share (a “Warrant Share”) at a price of US$0.25 per Warrant Share for a period of eighteen (18) months following closing of the Offering. Certain directors, officers and insiders of the Company may participate in the Private Placement.

The Company is cancelling its earlier announced intention to complete a non-brokered private placement financing, consisting of 17,000,000 Equity Units at US $0.20 per unit, to raise gross proceeds of up to US $3,400,000 (the “Private Placement”) due to market conditions and the increased dilution the larger proposed financing would have caused.

The securities issued will be subject to a hold period in Canada of four months and one day, or for any resales possible into the USA under Rule 144, six months and one day. Proceeds from the equity units will be used for corporate development in the Medical Marijuana business, G&A and general working capital. The Private Placement will be subject to normal regulatory approvals.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariabioscience.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forwardlooking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings.

There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No
statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release